Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism

Atherosclerosis

Volumn 222, Issue 2, 2012, Pages 375-381

  Breen, Danna M ^a   Dolinsky, Vernon W ^b   Zhang, Hangjun ^a   Ghanim, Husam ^c   Guo, June ^a   Mroziewicz, Margaret ^a   Tsiani, Evangelia L ^d   Bendeck, Michelle P ^a   Dandona, Paresh ^c   Dyck, Jason R B ^b   Heximer, Scott P ^a   Giacca, Adria ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY AT BUFFALO   (United States)

^d BROCK UNIVERSITY   (Canada)

Author keywords

Endothelial nitric oxide synthase; Neointima; Proliferation; Restenosis; Resveratrol

Indexed keywords

CD31 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; N(G) NITROARGININE METHYL ESTER; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA INJURY; ARTICLE; CAROTID ARTERY INJURY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FEMORAL ARTERY; MALE; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD31; AORTA; CARDIOVASCULAR AGENTS; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMORAL ARTERY; GENE EXPRESSION REGULATION; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOINTIMA; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STILBENES; TIME FACTORS; VASCULAR SYSTEM INJURIES;

EID: 84861345431     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.03.021     Document Type: Article

References (30)

1. Ghanim H., Sia C.L., Abuaysheh S., et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010, 95:E1-E8.
2. Ghanim H., Sia C.L., Korzeniewski K., et al. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab 2011, 96:1409-1414.
3. Do G.M., Kwon E.Y., Kim H.J., et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 2008, 374:55-59.
4. Gu J., Wang C.Q., Fan H., et al. Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-injured rats. J Cardiovasc Pharmacol 2006, 47:711-721.
5. Zou J., Huang Y., Cao K., et al. Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model. Life Sci 2000, 68:153-163.
6. Janssens S., Flaherty D., Nong Z., et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 1998, 97:1274-1281.
7. Moroi M., Zhang L., Yasuda T., et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 1998, 101:1225-1232.
8. Khandelwal A.R., Hebert V.Y., Dugas T.R. Essential role of ER-alpha-dependent NO production in resveratrol-mediated inhibition of restenosis. Am J Physiol Heart Circ Physiol 2010, 299:H1451-H1458.
9. Arnal J.F., Warin L., Michel J.B. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 1992, 90:647-652.
10. Ellenby M.I., Ernst C.B., Carretero O.A., Scicli A.G. Role of nitric oxide in the effect of blood flow on neointima formation. J Vasc Surg 1996, 23:314-322.
11. Breen D.M., Chan K.K., Dhaliwall J.K., et al. Insulin increases reendothelialization and inhibits cell migration and neointimal growth after arterial injury. Arterioscler Thromb Vasc Biol 2009, 29:1060-1066.
12. Sata M., Maejima Y., Adachi F., et al. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol 2000, 32:2097-2104.
13. Chan A.Y., Soltys C.L., Young M.E., Proud C.G., Dyck J.R. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 2004, 279:32771-32779.
14. Baur J.A., Pearson K.J., Price N.L., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
15. Oelze M., Mollnau H., Hoffmann N., et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 2000, 87:999-1005.
16. Duplain H., Burcelin R., Sartori C., et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001, 104:342-345.
17. Harris M.B., Mitchell B.M., Sood S.G., Webb R.C., Venema R.C. Increased nitric oxide synthase activity and Hsp90 association in skeletal muscle following chronic exercise. Eur J Appl Physiol 2008, 104:795-802.
18. Bhatt S.R., Lokhandwala M.F., Banday A.A. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur J Pharmacol 2011, 667:258-264.
19. Molnar J., Yu S., Mzhavia N., Pau C., Chereshnev I., Dansky H.M. Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice. Circ Res 2005, 96:1178-1184.
20. Morrow V.A., Foufelle F., Connell J.M., Petrie J.R., Gould G.W., Salt I.P. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 2003, 278:31629-31639.
21. Nagata D., Takeda R., Sata M., et al. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 2004, 110:444-451.
22. Bess E., Fisslthaler B., Fromel T., Fleming I. Nitric oxide-induced activation of the AMP-activated protein kinase alpha2 subunit attenuates IkappaB kinase activity and inflammatory responses in endothelial cells. PLoS One 2011, 6:20848.
23. Pacholec M., Bleasdale J.E., Chrunyk B., et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010, 285:8340-8351.
24. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005, 280:17187-17195.
25. Mattagajasingh I., Kim C.S., Naqvi A., et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 2007, 104:14855-14860.
26. Canto C., Gerhart-Hines Z., Feige J.N., et al. AMPK regulates energy expenditure by modulating NAD+metabolism and SIRT1 activity. Nature 2009, 458:1056-1060.
27. Marier J.F., Vachon P., Gritsas A., Zhang J., Moreau J.P., Ducharme M.P. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002, 302:369-373.
28. Calamini B., Ratia K., Malkowski M.G., et al. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J 2010, 429:273-282.
29. Yeung F., Hoberg J.E., Ramsey C.S., et al. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004, 23:2369-2380.
30. Perreault M., Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 2001, 7:1138-1143.